GSK 650394
目录号: PL04378 纯度: ≥99%
CAS No. :890842-28-1
商品编号 规格 价格 会员价 是否有货 数量
PL04378-5mg 5mg ¥989.09 请登录
PL04378-10mg 10mg ¥1582.55 请登录
PL04378-50mg 50mg ¥4747.64 请登录
PL04378-100mg 100mg 询价 询价
PL04378-200mg 200mg 询价 询价
PL04378-10mM*1mLinDMSO 10mM*1mLinDMSO ¥1088.00 请登录
Medlife所售产品仅用于科学研究(非临床研究),非药品不可食用,不可用于人体或动物的临床诊断和治疗,我们不为个人提供产品及服务。产品COA等资料,可至下方“质量控制”中下载。
中文名称
GSK 650394
中文别名
2-环戊基-4-(5-苯基-1H-吡咯并[2,3-b]吡啶-3-基)苯甲酸;GSK650394 抑制剂
英文名称
GSK 650394
英文别名
2-cyclopentyl-4-(5-phenyl-1H-pyrrolo[2,3-b]pyridin-3-yl)benzoic acid;GSK-650394;SureCN3767908;CHEMBL558642;CTK8F0693;CHEBI:665844;HMS2043A20;2-Cyclopentyl-4-(5-phenyl-1H-pyrrolo[2,3-b]pyridin-3-yl)-benzoic acid;GSK650394;2-Cyclopentyl-4-(5-phenyl-1H-pyrrolo[2,3-b]pyridin-3-yl-benzoicacid;GSK 650394;AK170277;56887611DJ;2-Cyclopentyl-4-(5-phenyl-1H-pyrrolo[2,3-b]pyridin-3-yl-benzoic acid;DXV;MLS006010262;GTPL8040;AOB4299;SYN5178;HMS3743K03;HMS3677P22;HMS3653A19;HMS3413P22;BCP08392;s7209;BDBM50296011;2441AH;Benzoic acid, 2-cyclopentyl-4-(5-phen
Cas No.
890842-28-1
分子式
C25H22N2O2
分子量
382.45
包装储存
Powder -20°C 3 years;4°C 2 years
产品详情
GSK 650394 是一种新颖的 SGK 抑制剂,在SPA实验中,对 SGK1 和 SGK2 的IC50 分别为 62 nM 和 103 nM。GSK 650394 还可抑制流感病毒复制。
生物活性
GSK 650394 is a novel SGK inhibitor with IC 50 of 62 nM and 103 nM for SGK1 and SGK2 in the SPA assay respectively. GSK 650394 also inhibits influenza virus replication.
性状
Solid
IC50 & Target[1][2]
SGK1
体外研究(In Vitro)
GSK650394 is relatively non-toxic, with LC50 values of 41 μM in M1 cells (68 times its activity IC50) and a LC50 greater than 100 μM in HeLa cells. GSK650394 inhibits SGK1-mediated epithelial transport with an IC50 of 0.6 μM in the SCC assay. GSK650394 inhibits the growth of LNCaP cells with IC50 of approximately 1 μM. GSK650394A inhibits the insulin-induced phosphorylation of PKB-Ser at 3 μM, and essentially abolishes this response at 10 μM. GSK650394A (1-10 μM) does not alter the phosphorylation of PRAS40-Ser246 in hormone-deprived cells or prevent the insulin-induced phosphorylation of this residue. has not independently confirmed the accuracy of these methods. They are for reference only.
体内研究(In Vivo)
GSK650394 (1, 10, and 30 μM, 10 μL/rat, intrathecally) dose-dependently prevents CFA-induced pain behavior and the associates SGK1 phosphorylation, GluR1 trafficking, and protein-protein interactions at 1 day after CFA administration. GSK650394 at concentrations of 10, 30, and 100 nM (10 μL), but not vehicle solution (SNL 3D+Veh and SNL 7D+Veh, respectively), dose-dependently increases the withdrawal latency of the ipsilateral hindpaw at 1-3 and 1-5 h after injection at days 3 and 7 postsurgery (SNL 3D+GSK and SNL 7D+GSK, respectively). GSK650394 (from day 0 to 6 postsurgery; 100 nM, 10 μL, i.t.) administration alleviates SNL-induced allodynia at days 3, 5, and 7 postsurgery in SNL animals. has not independently confirmed the accuracy of these methods. They are for reference only.
运输条件
Room temperature in continental US; may vary elsewhere.
储存方式
Powder -20°C 3 years;4°C 2 years
参考文献
[1]. Sherk AB, et al. Development of a small-molecule serum- and glucocorticoid-regulated kinase-1 antagonist and its evaluation as a prostate cancer therapeutic. Cancer Res. 2008 Sep 15;68(18):7475-83.
[2]. Mansley MK, et al. Effects of nominally selective inhibitors of the kinases PI3K, SGK1 and PKB on the insulin-dependent control of epithelial Na+ absorption. Br J Pharmacol. 2010 Oct;161(3):571-88.
溶解度数据
In Vitro: DMSO : ≥ 40.7 mg/mL (106.42 mM)配制储备液
搜索质检报告(COA)

1:一般建议:溶解度为Medlife测试数据,可能与文献描述存在差异。这是由于生产工艺和批次不同产生的正常现象。为了使其更好的溶解,请用37℃加热试管并在超声波水浴中震动片刻。不同批次产品溶解度各有差异,仅做参考,具体以实验方案为准。

2:储存条件:粉末-20°C一般情况可以保存3年,溶于溶剂-80°C一般情况可以保存1年。不同产品及不同批次产品可能存在差异,请细致阅读产品信息,并辅助参考相关文献描述。

The molarity calculator equation
Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)
The dilution calculator equation
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
This equation is commonly abbreviated as: C1V1 = C2V2